Transcatheter Heart Valves Market to Grow at 9.8% CAGR Through 2033

The Transcatheter Heart Valves Market is developing rapidly as less invasive options to open-heart surgery are becoming commonly accepted, particularly for patients at high or intermediate surgical risk. Advancements in valve design have improved procedural success rates by not only enhancing valve fit but reducing complications such as leaks and increasing device lifespan. The potential patient pool is expanding into new patient groups with lower surgical risk and younger patients. More experience and familiarity with transcatheter valve procedures among interventional cardiologists and cardiac surgeons and improved imaging capabilities to guide them has paved the road for its rapid acceptance.

Additionally, the development of valves for mitral and tricuspid applications is opening new therapeutic frontiers beyond the aortic valve. Despite challenges such as device cost and regulatory barriers, the market’s focus on improving patient outcomes and simplifying procedures continues to attract investment and innovation, signaling strong growth potential in both mature and emerging healthcare systems.

Check valuable insights in the Transcatheter Heart Valves Market report. You can easily get a sample PDF of the report - https://www.businessmarketinsights.com/sample/BMIPUB00031929

Transcatheter Heart Valves Market Size and Share Analysis

By valve type, the transcatheter heart valves market is segmented into aortic valve, mitral valve, pulmonary valve, and tricuspid valve. The aortic valve segment dominated the market in 2024. Aortic valves are the most dominant type because aortic stenosis, a narrowing of the aortic valve opening, is the most prevalent and life-threatening valvular heart disease, particularly in the aging population. The development of TAVR (Transcatheter Aortic Valve Replacement) procedures has made this a widely adopted and successful treatment.

By type, the transcatheter heart valves market is segmented into mechanical valves and bioprosthetic valves. The bioprosthetic valves segment dominated the market in 2024. Bioprosthetic valves dominate due to their lower risk of thrombosis, which means patients do not require long-term anticoagulation therapy. This is a significant advantage, especially for older patients, over mechanical valves that require lifelong blood-thinning medication.

By application, the transcatheter heart valves market is segmented into aortic valve regurgitation, mitral valve regurgitation, tricuspid regurgitation, and pulmonary valve regurgitation. The aortic valve regurgitation segment held the largest share of the market in 2024. Aortic valve regurgitation is the leading application due to the high global burden of aortic valve disorders, such as aortic stenosis and regurgitation. TAVR procedures, which are used to treat these conditions, are the most established and widely performed transcatheter valve interventions.

By end user, the market is segmented into hospitals, ambulatory surgical centers, and cardiac catheterization labs. The hospitals segment held the largest share of the market in 2024. Hospitals dominate as the end user segment because transcatheter heart valve procedures are complex, require a specialized cardiac catheterization lab, and involve a multidisciplinary team of interventional cardiologists and cardiac surgeons. Hospitals provide the necessary infrastructure and expertise for these high-volume and resource-intensive interventions.

Market leaders and key company profiles

• Medtronic plc
• Boston Scientific Corporation
• Abbott
• Edwards Lifesciences Corporation
• Meril Life Sciences
• Artivion, Inc
• Venus Medtech (Hangzhou) Inc. 
• SMT 
• TTK Healthcare Limited
• Products & Features GmbH

Transcatheter Heart Valves Market News and Key Development:

The transcatheter heart valves market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the key developments in the transcatheter heart valves market are:

• In May 2025, Abbott announced the U.S. Food and Drug Administration (FDA) has approved the company's Tendyne™ transcatheter mitral valve replacement (TMVR) system to treat people with mitral valve disease.
• In May 2025, Edwards Lifesciences announced that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy, the SAPIEN 3 platform, for severe aortic stenosis (AS) patients without symptoms, marking the first FDA approval for TAVR in asymptomatic patients.
• In April 2025, Edwards Lifesciences Corporation announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment of patients with symptomatic mitral regurgitation.

Get Premium Research Report of Transcatheter Heart Valves Market Size and Growth Report at: https://www.businessmarketinsights.com/buy/BMIPUB00031929

About Us:

Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Defense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications.

Contact us:

• If you have any questions about this report or would like further information, please contact us:
• Contact person: Ankit Mathur
• Email: sales@businessmarketinsights.com
• Phone: +16467917070